FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1483338207> ?p ?o ?g. }

• W1483338207 endingPage "611" @default.
• W1483338207 startingPage "602" @default.
• W1483338207 abstract "BACKGROUND: The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain. METHODS: In this centrally randomized phase 2 study, the authors compared 2 different strategies of RIC. In total, 139 patients (median age, 54 years; range, 21-65 years) with hematologic malignancies underwent allo-HSCT from a human leukocyte antigen-identical sibling after conditioning combining fludarabine with either busulfan and rabbit antithymocyte-globulin (BU-rATG) (n = 69) or total body irradiation (TBI) (n = 70). Postgraft immunosuppression consisted of cyclosporin A in all patients with the addition of mycophenolate-mophetil after TBI. RESULTS: The median follow-up was 54 months (range, 26-88 months). One-year overall survival rate was identical in both groups. Four patients experienced graft-failure after TBI. The incidence of grade 2 through 4 acute graft-versus-host-disease was greater after BU-rATG than after TBI (47% vs 27%; P = .01), whereas no difference was observed with chronic graft-versus-host-disease. The BU-rATG group had a higher objective response rate (65% vs 46%; P = .05) and a lower relapse rate (27% vs 54%; P < .01). However, the nonrelapse mortality rate was higher after BU-rATG than after TBI (38% vs 22%; P = .027). At 5 years, the overall and progression-free survival rates were 41% and 29%, respectively, and did not differ statistically between groups. A detrimental effect on some parameters of quality of life was more pronounced after BU-rATG, but recovery was identical in both groups. The mean total cost per patient, including the cost to treat disease progression post-transplantation, did not differ statistically between groups. CONCLUSIONS: Five years after transplantation, the BU-rATG regimen was associated with greater disease control. However, because of the higher nonrelapse mortality rate, this did not translate into better overall or progression-free survival. Cancer 2013. © 2012 American Cancer Society." @default.
• W1483338207 created "2016-06-24" @default.
• W1483338207 creator A5013205657 @default.
• W1483338207 creator A5020996390 @default.
• W1483338207 creator A5021060422 @default.
• W1483338207 creator A5022161221 @default.
• W1483338207 creator A5034473496 @default.
• W1483338207 creator A5045967298 @default.
• W1483338207 creator A5047798037 @default.
• W1483338207 creator A5053452922 @default.
• W1483338207 creator A5059403965 @default.
• W1483338207 creator A5059804319 @default.
• W1483338207 creator A5061348202 @default.
• W1483338207 creator A5064496263 @default.
• W1483338207 creator A5069084023 @default.
• W1483338207 creator A5069761611 @default.
• W1483338207 creator A5072027146 @default.
• W1483338207 creator A5072557528 @default.
• W1483338207 creator A5086317399 @default.
• W1483338207 date "2012-08-14" @default.
• W1483338207 modified "2023-10-13" @default.
• W1483338207 title "Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation" @default.
• W1483338207 cites W1479909146 @default.
• W1483338207 cites W1508187469 @default.
• W1483338207 cites W1544569979 @default.
• W1483338207 cites W1965979673 @default.
• W1483338207 cites W1982439911 @default.
• W1483338207 cites W1982912364 @default.
• W1483338207 cites W2017978806 @default.
• W1483338207 cites W2024390130 @default.
• W1483338207 cites W2034768872 @default.
• W1483338207 cites W2052605694 @default.
• W1483338207 cites W2053278212 @default.
• W1483338207 cites W2069306963 @default.
• W1483338207 cites W2069377065 @default.
• W1483338207 cites W2076796722 @default.
• W1483338207 cites W2082921707 @default.
• W1483338207 cites W2093010852 @default.
• W1483338207 cites W2106947293 @default.
• W1483338207 cites W2107611068 @default.
• W1483338207 cites W2121844342 @default.
• W1483338207 cites W2137489389 @default.
• W1483338207 cites W2159773146 @default.
• W1483338207 cites W2162944053 @default.
• W1483338207 cites W2166599801 @default.
• W1483338207 cites W2167571044 @default.
• W1483338207 cites W2242587738 @default.
• W1483338207 cites W2314356636 @default.
• W1483338207 cites W2319650146 @default.
• W1483338207 cites W4246085869 @default.
• W1483338207 cites W4293241248 @default.
• W1483338207 doi "https://doi.org/10.1002/cncr.27786" @default.
• W1483338207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22893313" @default.
• W1483338207 hasPublicationYear "2012" @default.
• W1483338207 type Work @default.
• W1483338207 sameAs 1483338207 @default.
• W1483338207 citedByCount "66" @default.
• W1483338207 countsByYear W14833382072012 @default.
• W1483338207 countsByYear W14833382072013 @default.
• W1483338207 countsByYear W14833382072014 @default.
• W1483338207 countsByYear W14833382072015 @default.
• W1483338207 countsByYear W14833382072016 @default.
• W1483338207 countsByYear W14833382072017 @default.
• W1483338207 countsByYear W14833382072018 @default.
• W1483338207 countsByYear W14833382072019 @default.
• W1483338207 countsByYear W14833382072020 @default.
• W1483338207 countsByYear W14833382072021 @default.
• W1483338207 countsByYear W14833382072022 @default.
• W1483338207 countsByYear W14833382072023 @default.
• W1483338207 crossrefType "journal-article" @default.
• W1483338207 hasAuthorship W1483338207A5013205657 @default.
• W1483338207 hasAuthorship W1483338207A5020996390 @default.
• W1483338207 hasAuthorship W1483338207A5021060422 @default.
• W1483338207 hasAuthorship W1483338207A5022161221 @default.
• W1483338207 hasAuthorship W1483338207A5034473496 @default.
• W1483338207 hasAuthorship W1483338207A5045967298 @default.
• W1483338207 hasAuthorship W1483338207A5047798037 @default.
• W1483338207 hasAuthorship W1483338207A5053452922 @default.
• W1483338207 hasAuthorship W1483338207A5059403965 @default.
• W1483338207 hasAuthorship W1483338207A5059804319 @default.
• W1483338207 hasAuthorship W1483338207A5061348202 @default.
• W1483338207 hasAuthorship W1483338207A5064496263 @default.
• W1483338207 hasAuthorship W1483338207A5069084023 @default.
• W1483338207 hasAuthorship W1483338207A5069761611 @default.
• W1483338207 hasAuthorship W1483338207A5072027146 @default.
• W1483338207 hasAuthorship W1483338207A5072557528 @default.
• W1483338207 hasAuthorship W1483338207A5086317399 @default.
• W1483338207 hasConcept C120665830 @default.
• W1483338207 hasConcept C121332964 @default.
• W1483338207 hasConcept C126322002 @default.
• W1483338207 hasConcept C141071460 @default.
• W1483338207 hasConcept C168563851 @default.
• W1483338207 hasConcept C2776694085 @default.
• W1483338207 hasConcept C2776755627 @default.
• W1483338207 hasConcept C2777408962 @default.
• W1483338207 hasConcept C2778880498 @default.
• W1483338207 hasConcept C2779263901 @default.
• W1483338207 hasConcept C2779972918 @default.

• next